ATAGI has released new advice relating to the administration of further COVID-19 vaccines.
The need and frequency of further doses beyond a primary course depends on the age of the recipient and their level of immunocompromise:
- All individuals aged 75 years and over- recommended to receive a dose every 6 months
- All individuals aged 65 to 74 years- recommended to receive a dose every 12 months, but can consider a dose every 6 months
- Individuals with severe immunocompromise aged 18 to 64 years- recommended to receive a dose every 12 months, but can consider a dose every 6 months
- Individuals without severe immunocompromise aged 18 to 64- can consider a dose every 12 months
- Individuals with severe immunocompromise aged 5 to 17 years- can consider a dose every 12 months
- Individuals without severe immunocompromise aged 5 to 17 years- not recommended to receive further doses
- Individuals less than 5 years- not recommended to receive further doses.
Omicron XBB1.5 vaccines are preferred for all primary and subsequent doses in all ages. There is currently no supply of the Comirnaty Omicron XBB1.5 formulation for children aged 6 months- 4 years however it is anticipated to be available later in 2024. Until this time providers should continue using the age-appropriate Comirnaty original formulation for this group.
For more information refer to: ATAGI statement on the administration of COVID-19 vaccines in 2024